Literature DB >> 2414406

Plasma and gamma-globulin infusion in chronic inflammatory polyneuropathy.

M Vermeulen, F G van der Meché, J D Speelman, A Weber, H F Busch.   

Abstract

We treated 17 patients with chronic inflammatory polyneuropathy (CIP) with infusions of fresh-frozen plasma (FFP). Thirteen patients had a beneficial response: 12 improved considerably and one moderately. The first signs of improvement were seen within 8 days of the onset of treatment. None of these patients had had spontaneous remissions for 2 months prior to treatment, and none had received immunosuppressive medication during the plasma infusions. The treatment effect was short-lasting in 9 patients. Re-institution of the FFP infusions was always followed by improvement. The same effect could be achieved by intravenous gamma-globulin. We conclude that infusions with FFP, of which the IgG fraction is the effective part, may induce a rapid and clinically important improvement in patients with CIP.

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 2414406     DOI: 10.1016/0022-510x(85)90173-x

Source DB:  PubMed          Journal:  J Neurol Sci        ISSN: 0022-510X            Impact factor:   3.181


  32 in total

1.  A history of immune globulin therapy, from the Harvard crash program to monoclonal antibodies.

Authors:  Melvin Berger
Journal:  Curr Allergy Asthma Rep       Date:  2002-09       Impact factor: 4.806

Review 2.  Management of chronic inflammatory demyelinating polyradiculoneuropathy.

Authors:  Richard A C Hughes
Journal:  Drugs       Date:  2003       Impact factor: 9.546

Review 3.  Basic principles of intravenous immunoglobulin (IVIg) treatment.

Authors:  Martin Stangel; Refik Pul
Journal:  J Neurol       Date:  2006-09       Impact factor: 4.849

Review 4.  Intravenous immunoglobulin (IVIG) for the therapy of autoimmune disorders.

Authors:  S A Schwartz
Journal:  J Clin Immunol       Date:  1990-03       Impact factor: 8.317

5.  Pulsed high dose dexamethasone treatment in chronic inflammatory demyelinating polyneuropathy: a pilot study.

Authors:  D S Molenaar; P A van Doorn; M Vermeulen
Journal:  J Neurol Neurosurg Psychiatry       Date:  1997-04       Impact factor: 10.154

6.  Dosing and individualized treatment - patient-centric treatment: changing practice guidelines.

Authors:  H S Patwa
Journal:  Clin Exp Immunol       Date:  2014-12       Impact factor: 4.330

7.  Intravenous immunoglobulin treatment in patients with chronic inflammatory demyelinating neuropathy not responsive to other treatments.

Authors:  R Nemni; S Amadio; R Fazio; G Galardi; S Previtali; G Comi
Journal:  J Neurol Neurosurg Psychiatry       Date:  1994-11       Impact factor: 10.154

Review 8.  Intravenous immunoglobulin treatment in patients with chronic inflammatory demyelinating polyneuropathy.

Authors:  P A van Doorn
Journal:  J Neurol Neurosurg Psychiatry       Date:  1994-11       Impact factor: 10.154

9.  Overview of the pathogenesis and treatment of chronic inflammatory demyelinating polyneuropathy with intravenous immunoglobulins.

Authors:  Mohamed Mahdi-Rogers; Yusuf A Rajabally
Journal:  Biologics       Date:  2010-03-24

10.  Current proposed mechanisms of action of intravenous immunoglobulins in inflammatory neuropathies.

Authors:  Saiju Jacob; Yusuf A Rajabally
Journal:  Curr Neuropharmacol       Date:  2009-12       Impact factor: 7.363

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.